

## Remarks

Claims 1-18 were pending.


Claims 1-18 are cancelled.

Claims 19-33 are new.

The application now contains claims 19-33.

Claims 19-32 are fully supported by the originally filed claims. All material withdrawn by the Examiner is removed and all existing claims relate to the device of original claims 10-12. New claim 19 incorporates the limitations from original claims 10, 1, 4 and 5; claims 20 and 21 correlate with original claims 11 and 12. The additional limitations of claims 22-32 are found in the original claims dependent on claim 1. No new matter is added.

The elected species with which to begin prosecution, compound B-9 of example 6, pages 58-59 of the instant Specification, is encompassed by the devices of claims 19-21, 21 and 32.



B-9

## Rejections


Claims 10-13 were rejected under 35 USC 112 second paragraph as being device claims which referred back to a compound claim. Claim 19, from which all instant claims depend, is a stand alone claim incorporating limitations from now cancelled compound claims. Applicants submit that the rejections under 35 USC 112 second paragraph have been addressed and are overcome and kindly ask they be withdrawn.

The claims are rejected under the doctrine of obviousness type double patenting over US Pat 7,541,096. Applicants enclose a terminal disclaimer over US Pat 7,541,096 and therefore kindly ask that the of obviousness type double patenting rejections be withdrawn.

The claims are rejected under 35 USC 102(b) as anticipated by Roitman, US 5,629,389 which discloses the use of benzotriazole UVA's in EL devices. The Bzt's of '396 are 2-hydroxy Bzt's and being UVA's, the presence of the 2-hydroxy group is essential. The device of the instant claims contains Bzt compounds specifically without a free OH in the 2-position. Applicants respectfully submit that there is no anticipation and kindly ask that the rejections under 35 USC 102(b) over Roitman, US 5,629,389 be withdrawn.

Applicants respectfully submit that all rejections are addressed and are overcome and kindly ask that they be withdrawn and claims 19-33 be found allowable. In the event that minor amendments will further prosecution, Applicants request that the examiner contact the undersigned representative.

Respectfully submitted,



Joseph C. Suhadolnik  
Agent for Applicants  
Reg. No. 56,880  
filed under 37 CFR 1.34(a)

Ciba Specialty Chemicals Corporation  
Patent Department  
540 White Plains Road  
P.O. Box 2005  
Tarrytown, NY 10591-9005  
Tel. (914) 785-2973  
Fax (914) 785-7102

Enclosed: Terminal disclaimer over US Pat 7,541,096